Rosetta Genomics (OTCMKTS:ROSGQ) is a molecular diagnostics company that leverages microRNA (miRNA) biomarkers to develop tests for the accurate diagnosis and prognosis of cancer and other diseases. Its proprietary platform analyzes the unique expression patterns of miRNAs—small, non-coding RNA molecules that regulate gene expression—to distinguish between tumor types, predict disease progression and guide treatment decisions. Through its CLIA-certified laboratories, the company offers laboratory-developed tests designed to address challenging diagnostic needs in oncology, including tumors of unknown origin and differential diagnosis of thyroid nodules.
The company’s product pipeline has historically included assays such as RosettaGX Reveal, which aids in the evaluation of thyroid nodules with indeterminate cytology, and RosettaGX Cancer Origin, intended to help identify the tissue of origin in metastatic cancers. Beyond its in-house tests, Rosetta Genomics has provided contract research services to pharmaceutical and biotechnology partners, applying its miRNA profiling expertise to biomarker discovery and companion diagnostic development. These collaborative projects span preclinical studies through clinical validation, supporting drug development programs focused on oncology and other therapeutic areas.
Founded in 2000 as a spin-out from the Weizmann Institute of Science in Rehovot, Israel, Rosetta Genomics went public in 2007. The company has maintained operations in both Israel and the United States, with research and development activities based in Rehovot and a CLIA-certified laboratory in New York. Over its history, Rosetta Genomics has established partnerships and regulatory clearances in Europe and select international markets, aiming to extend its miRNA-based testing solutions to a global customer base.
Rosetta Genomics is led by a management team with extensive experience in molecular diagnostics, biotechnology and commercial operations. The company continues to pursue strategic collaborations and regulatory approvals to expand its suite of miRNA-based assays and contract research offerings, supporting personalized medicine initiatives and addressing unmet needs in cancer diagnosis worldwide.
AI Generated. May Contain Errors.